Clinical Trial Search

Primary: Survival Free of Atrial Fibrillation — 28; 31 participants

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat

Primary: Change in AF Burden — -0.4; -2.4 percentage of time in AF

Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV

Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects

Primary: Time to First Atrial Fibrillation (AF) Recurrence or Atrial Flutter Emergence Defined by the Time to First Episode of AF or Atrial Flutter Lasting for at Least 10…

Primary: Proportion of Days Covered — 1.0; 0.9 Proportion of days covered — p=0.22

Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…

Primary: Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure — 92.7; 88.9 % of participants — p=0.2179

Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants

Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048

Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants

Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants

Primary: Rate of Recurrence of Atrial Arrhythmias — 0.132; 0.091 episodes per person-month of follow-up — p=0.05

Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…

Primary: Number of Participants With Acute Success — 53 Participants

Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants

Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms

Primary: Number of Days on Anticoagulation — 24.9 days

Primary: Percent of Subjects With a Primary Adverse Event — 3; 2 Participants — p=<0.0001

Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001

Primary: Atrial Fibrillation Dominant Frequency

Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants

Primary: Safety at 30 Days — 1 Participants

Primary: Number of Participants With Device or Procedure-related Serious Adverse Events — 12; 2 Participants

Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016

Primary: The Number of Patients in Sinus Rhythm at 12 Months. — 12 Participants

Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001

Primary: Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure — 95; 60 Percentage of participants